Compare AMTD & INMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AMTD | INMB |
|---|---|---|
| Founded | 2003 | 2015 |
| Country | France | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 71.2M | 64.7M |
| IPO Year | 2019 | 2018 |
| Metric | AMTD | INMB |
|---|---|---|
| Price | $0.73 | $2.35 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $5.40 |
| AVG Volume (30 Days) | 8.0K | ★ 327.1K |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 11.85 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $50,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $1.31 | ★ N/A |
| Revenue Growth | N/A | ★ 257.14 |
| 52 Week Low | $0.71 | $1.09 |
| 52 Week High | $1.65 | $2.60 |
| Indicator | AMTD | INMB |
|---|---|---|
| Relative Strength Index (RSI) | 45.27 | 54.39 |
| Support Level | $0.71 | $2.21 |
| Resistance Level | $0.80 | $2.55 |
| Average True Range (ATR) | 0.04 | 0.15 |
| MACD | -0.00 | -0.03 |
| Stochastic Oscillator | 41.87 | 58.27 |
AMTD IDEA Group is a diversified institution and digital solutions conglomerate group, connecting companies and investors with world-wide markets. The group operates its businesses in five reportable and operating segments: capital market solutions segment, digital solutions and other services segment, media and entertainment segment, hotel operations, hospitality and VIP services segment, and strategic investment segment. The group generates the majority of its revenue from the strategic investment segment that engages in proprietary investments and management of world-wide investment portfolio (including listed and unlisted equity shares investments and movie rights investments). Its geographic areas are China, Europe, America, and Southeast Asia.
INmune Bio Inc is a clinical stage biotechnology pharmaceutical company focused on developing and commercializing its product candidates to treat diseases where inflammation and immunology cause a dysfunctional immune system contributing to disease. The company's pipeline products include INKmune, XPro1595, and others. It has three product platforms; The CORDStrom product platform, The DN-TNF product platform, and The Natural Killer Cell Priming Platform.